JANUARY 14
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil

Therapeutic
Area

  • CONTACT US
  • RECRUIT
  1. Rare Disease
  2. Immune mediated
    inflammatory Disease
  3. Infectious Disease
  4. Oncology
  • Rare Disease
    지도
    Challenges in developing drugs for Rare Disorders

    A rare disease is any disease for which the number of affected patients is below a certain level. In U.S., it is less than 200,000 patients per disease, and in South Korea it is less than 20,000 patients per disease (based on U.S. FDA and Korea FDA information). According to the WHO, nearly 7,000 rare diseases have been reported so far and 3.5 - 5.9% of the worldwide population are suffering from one or more rare disorders. There are about 700 drugs approved by the U.S. FDA and it covers only 5% of entire rare diseases, leaving huge unmet medical needs in the field.

    Rare diseases are generally caused by genetic defects, thus its pathophysiology is with dysfunctional proteins. An emerging mRNA technology can produce proteins of interest efficiently when delivered to the body by using the host as a bioreactor. MOGAM believes that mRNA medicine will open the new door for protein replacement therapy and it will meet the unmet medical needs of numerous rare disorders.

    The symptoms of rare diseases are biologically complex to understand and it can be challenging to uncover its genomic or pathological drivers. Replacing the missing protein using mRNA technology is the first step we take for a new treatment. And our scientific dedication to understand the complexity of disease conditions will further advance the treatment.

    MOGAM hopes that mRNA therapy will ease the physical, financial and psychological burdens on patients with rare diseases and their families.

  • Immune mediated
    inflammatory Disease
    MOGAM is working to control the over-active immune response that causes immune mediated inflammatory diseases

    The immune system is the defender against foreign pathogens and hazardous substances. However, an over-active immune response can be an enemy. Immune mediated inflammatory disorders are diseases or conditions caused by a dysfunction or dysregulation of the immune system that include allergy, asthma and autoimmune diseases. These painful conditions impact on patient’s quality of life, such as stress, anxiety and depression. and many of these diseases are poorly managed by existing treatments that aim at reducing the signs and symptoms of the disease.

    MOGAM works to unravel the fundamental and important pathways of immune mediated inflammatory disease

    Many immune cells communicate and collaborate with each other or with other cells in tissues to activate immune response or inflammation. In immune mediated inflammatory disease, the most challenge is the complexity of the disease that is caused by many genetic and environmental factor. We work to unravel to know the exact cell types and mechanisms involved in diseases and then to figure out how to target them without disrupting the entire immune system.

    MOGAM is looking to develop new mechanisms of action with multi-targeted approaches in immune mediated inflammation

    Most of the drugs in clinical use today are designed with a single molecule in the body. Effectively addressing the multifaceted nature of immune mediated inflammatory diseases requires the development of a drug that can interact with multiple targets. Multi-targeted drugs offer important benefits from a therapeutic point of view for immune mediated inflammatory disease.

  • Infectious Disease
    Infectious diseases are disorders caused by pathogenic microorganisms, such as bacteria, fungi, parasites, or viruses

    A numerous variety of microorganisms are found nearly everywhere in our environment. Although they are normally harmless or even helpful, some microorganisms called pathogens can cause diverse infectious diseases, including chickenpox, flu, herpes zoster, pneumonia, or coronavirus disease. Diverse infectious diseases continue to be a globally significant burden of disease.

    MOGAM is conducting research on developing vaccines and therapeutics to prevent or treat infectious diseases

    MOGAM is currently searching for new approaches to prevent or treat diverse infectious diseases, based on the study of infectious mechanisms of pathogens.

  • Oncology
    Immunotherapy Immune Modulation & Anti-Tumor Effects

    Immunotherapy initially comprised the therapeutic application of cytokines, such as interleukins and interferons, which improve the overall function of the immune system. This was followed by the development of T cell therapies that elicit immune reactions against specific antigens, antigen-derived peptide drugs that boost immune reactions against target antigens, monoclonal antibodies that target specific tumor antigens, and most recently, immuno-regulatory antibodies that block immunosuppressive molecules.

    Targeted cancer drugs

    Targeted therapy can block growth, proliferation, angiogenesis, and invasion and metastasis by targeting receptors or signaling pathways that are abnormal. Because this method targets specific receptors and signaling molecules, it is possible to use specific biomarkers to predict which patients may benefit the most from this therapy.

    A key obstacle against success of anti-cancer drug is unwanted adverse effects. To overcome such problems, molecular-targeted drugs have been developed, which specifically attack growth factor receptors or signaling effectors that are dysregulated in cancer. Molecular-targeted therapeutics successfully block cancer cell proliferation, angiogenesis, and invasion/metastasis with relatively less severe side effects compared with cytotoxic drugs. Clinical studies show that targeted drugs in combination with conventional cytotoxic therapies (e.g., chemotherapy, radiotherapy) significantly extended survival rates of cancer patients who have no other treatment options.

    Currently more innovative approaches are actively under development to provide benefits to cancer patients with more efficacy and less side effects. Those include T-cell engaging antiboides, immune cell regulating antibodies (include immune checkpoint blockade) and multi-specific therapy. Selecting the right patients who can benefit from the treatment is also an important area of current research trends.

    MOGAM is on the front line of research and development of cancer therapeutics. Not only finding the preclinical candidates by efficacy study, we find competitive advantage of therapeutic candidates by mode of action and translation study. We strongly believe that patients can benefit from the right treatment options and this is only achieved from solid scientific research.